Warminster-based Arbutus Biopharma laid off over half of its workforce and is exiting its headquarters to conserve cash while ...

Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 15.0% ...

The restructuring is only the latest round of layoffs to hit Arbutus after the company shed 40% of its staff and cut back on ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The ...

Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.

The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in ...

Is Arbutus Biopharma (ABUS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Arbutus Biopharma (NASDAQ:ABUS) stock gains as the company announces a restructuring drive with a 57% workforce reduction.

In March 2025, the Company’s Board took action to reduce the Company’s workforce by 57% resulting in a total workforce after reductions of 19 ...

Reports FY24 revenue $6.171M, consensus $8.72M. “With my recent appointment as CEO of Arbutus, I am excited to lead the company into its next ...